secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-137861
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics appoints Dr. David Shapiro to Board as Class III director
-----------------------------------------------------------------------------

- Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.
- Receives annual cash retainer of $40k for Board service and $5k for Nominating Committee service.
- Received initial option grant of 60k shares (3-year monthly vest) and prorated annual option of 7.5k shares (1-year vest).
- Also appointed to the Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/0001193125-26-137861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/dsgn-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-137861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer